Washington Floods: Recovery Amid Ongoing Risks

The Daily Brief — Wednesday, December 17, 2025

A concise, nonpartisan roundup from roughly the past 24 hours. Focused on signal, incentives, and what could matter to outcomes.

US News

  • Washington floods claim first reported life; recovery and risk continue
    • After a week of atmospheric-river storms, officials reported the first flood-related death near Seattle as rescues and damage assessments continue across western Washington. Elevated river levels and landslide risks persist even as rain eases. (theguardian.com)
  • House floor vote highlights culture‑policy fault line
    • The House took up Rep. Marjorie Taylor Greene’s bill to criminalize gender‑affirming care for minors nationwide. Passage is uncertain and prospects in the Senate are low, but the vote underscores intensifying federal‑level efforts to regulate medical standards for youth. (washingtonpost.com)
  • Early‑season snowfall split
    • A disrupted polar vortex produced one of the snowiest early Decembers in the Upper Midwest and Great Lakes while the Pacific Northwest ran warmer and wetter—exacerbating flood risk. (washingtonpost.com)

Global News

  • Ukraine: fresh strikes and contested battlefield claims
    • Russian guided‑bomb attacks hit Zaporizhzhia, wounding at least 26, while Kyiv said it had retaken most of Kupiansk—claims Moscow disputes. Expect continued artillery and air pressure even as diplomats explore security arrangements. (reuters.com)
  • Kremlin rhetoric hardens
    • President Putin told defense officials Russia would not compromise on war aims and predicted political turnover among Ukraine’s European backers—signaling limited near‑term room for talks absent battlefield shifts. (ft.com)

Science

  • FDA clears twice‑yearly biologic for severe asthma
    • The agency approved GSK’s depemokimab (Exdensur) as a twice‑yearly add‑on for severe eosinophilic asthma in patients 12+, offering a lower‑frequency alternative to existing biologics. Labeling for nasal‑polyps was not granted. (reuters.com)
  • Oncology momentum continues
    • The FDA expanded first‑line use of Enhertu (AstraZeneca/Daiichi) with Perjeta in HER2‑positive metastatic breast cancer, with substantially longer progression‑free survival vs. standard of care. (reuters.com)

Technology

  • Amazon in talks to invest about $10B in OpenAI
    • Negotiations under discussion could value OpenAI above $500B and include use of Amazon’s Trainium chips, potentially reshaping cloud alliances in AI compute. Talks are fluid; Microsoft remains a major shareholder. (reuters.com)
  • Google settlements and compliance pressure
    • Consumer payouts from the states’ Google Play case are ramping, while EU regulators signal additional DMA‑related fines if Google’s proposed remedies fall short—extending multi‑front antitrust pressure into 2026. (statesman.com)

Business

  • Oil rebounds on Venezuela sanction shock
    • Brent and WTI rose ~2% after the U.S. ordered a “total blockade” on sanctioned tankers entering or leaving Venezuela, tightening perceived supply amid otherwise weak demand signals. Energy equities firmed. (reuters.com)
  • UK equities rally on disinflation and rate‑cut bets
    • Softer U.K. inflation boosted expectations for a Bank of England cut, lifting banks and cyclicals; oil’s bounce added support to energy names. (reuters.com)

Munger‑style takeaways

  1. Follow the compute incentives. If Amazon joins OpenAI’s capex stack alongside Microsoft and others, the real story is unit economics: chip supply, price/performance per token, and cloud lock‑ins. Partnerships that lower delivered flops/$ will capture margin; the rest are headlines. (reuters.com)
  2. Policy overhangs set tech’s boundary conditions. U.S. settlements and EU DMA enforcement won’t kill scale players, but they can redirect cash flows (distribution fees, defaults, data access) and open lanes for rivals and intermediaries. (statesman.com)
  3. Frequency matters in medicine economics. A twice‑yearly asthma biologic can shift adherence and payer math versus monthly dosing—watch real‑world uptake and payer coverage decisions, not just trial endpoints. (reuters.com)
  4. Geopolitics trumps models, for a day. Oil at multi‑year lows snapped back on one order about Venezuelan barrels—reminder that price paths hinge on policy switches, not just demand curves. (reuters.com)

Time reference: Reporting reflects updates published through Wednesday, December 17, 2025 (U.S. Eastern).